OTCMKTS:ATBPF - Antibe Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.95
  • Forecasted Upside: 133.82 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.40
▼ -0.2 (-5.56%)
1 month | 3 months | 12 months
Get New Antibe Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATBPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATBPF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.95
▲ +133.82% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Antibe Therapeutics in the last 3 months. The average price target is $7.95, with a high forecast of $14.50 and a low forecast of $1.40. The average price target represents a 133.82% upside from the last price of $3.40.
Buy
The current consensus among 3 polled investment analysts is to buy stock in Antibe Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
2/25/2021Canaccord GenuityLower Price TargetBuy$16.50 ➝ $14.50
i
2/10/2021Canaccord GenuityBoost Price TargetBuy$15.00 ➝ $16.50
i
Rating by Tania Gonsalves at Canaccord Genuity
2/2/2021Maxim GroupReiterated RatingBuy
i
9/24/2020Maxim GroupInitiated CoverageBuy
i
9/4/2020Echelon Wealth PartnersReiterated RatingBuy$1.40
i
8/17/2020Canaccord GenuityInitiated CoverageBuy$1.50
i
Rating by Tania Gonsalves at Canaccord Genuity
(Data available from 4/21/2016 forward)
Antibe Therapeutics logo
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $3.40
$3.34
$3.54

50 Day Range

MA: $3.92
$3.56
$4.34

52 Week Range

Now: $3.40
$2.21
$6.40

Volume

34,714 shs

Average Volume

50,027 shs

Market Capitalization

$155.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Antibe Therapeutics?

The following Wall Street analysts have issued reports on Antibe Therapeutics in the last year: Canaccord Genuity, Echelon Wealth Partners, and Maxim Group.
View the latest analyst ratings for ATBPF.

What is the current price target for Antibe Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Antibe Therapeutics in the last year. Their average twelve-month price target is $7.95, suggesting a possible upside of 133.8%. Canaccord Genuity has the highest price target set, predicting ATBPF will reach $14.50 in the next twelve months. Echelon Wealth Partners has the lowest price target set, forecasting a price of $1.40 for Antibe Therapeutics in the next year.
View the latest price targets for ATBPF.

What is the current consensus analyst rating for Antibe Therapeutics?

Antibe Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATBPF will outperform the market and that investors should add to their positions of Antibe Therapeutics.
View the latest ratings for ATBPF.

What other companies compete with Antibe Therapeutics?

How do I contact Antibe Therapeutics' investor relations team?

Antibe Therapeutics' physical mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. The company's listed phone number is 416-922-3460 and its investor relations email address is [email protected] The official website for Antibe Therapeutics is www.antibethera.com.